Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Suzanne Forry, Ph.D.

Program Director
Lead Program Director, Glioblastoma Therapeutics Network
Developmental Therapeutics Program
Preclinical Therapeutics Grants Branch
240-276-5922
|
forryscs@mail.nih.gov

Dr. Suzanne Forry attained her Ph.D. in anatomy and cell biology from the University of Pennsylvania School of Medicine. She joined the National Institutes of Health (NIH) in 2004 as a Scientific Review Official at the Center for Scientific Review. Prior to joining NIH, Dr. Forry directed the gene therapy oncology programs at Genetic Therapy, Incorporated, a wholly-owned subsidiary of Novartis. In this role, her laboratory focused on cancer immunotherapy. Dr. Forry joined the Preclinical Therapeutics Grants Branch at the National Cancer Institute (NCI) as a Program Director in 2008 where she manages a portfolio of research grants spanning from drug discovery through pre-clinical studies supporting future clinical trials. She is currently a point person for a funding opportunity on cancer drug screening, and leads the Glioblastoma Therapeutics Network (GTN), an effort to move novel therapeutic agents for adult glioblastoma multiforme (GBM) from preclinic to early stage clinical trials. Dr. Forry's portfolio spans all cancer types. Areas of focus are strategies to inhibit mutant KRAS, and mechanisms of action and resistance to targeted therapies with particular focus on lung and brain cancers.

Email